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xpression levels of long non-coding RNA (lncRNA) have been
shown to associate with clinical outcome of patients with cytogenetically normal acute myeloid leukemia (CN-AML). However, the
frequency and clinical significance of genetic variants in the nucleotide
sequences of lncRNA in AML patients is unknown. Herein, we analyzed
total RNA sequencing data of 377 younger adults (aged <60 years) with
CN-AML, who were comprehensively characterized with regard to clinical outcome. We used available genomic databases and stringent filters
to annotate genetic variants unequivocally located in the non-coding
transcriptome of AML patients. We detected 981 variants, which are
recurrently present in lncRNA that are expressed in leukemic blasts.
Among these variants, we identified a cytosine-to-thymidine variant in
the lncRNA RP5-1074L1.4 and a cytosine-to-thymidine variant in the
lncRNA SNHG15, which independently associated with longer survival
of CN-AML patients. The presence of the SNHG15 cytosine-to-thymidine variant was also found to associate with better outcome in an independent dataset of CN-AML patients, despite differences in treatment
protocols and RNA sequencing techniques. In order to gain biological
insights, we cloned and overexpressed both wild-type and variant ver-
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sions of the SNHG15 lncRNA. In keeping with its negative prognostic impact, overexpression of the
wild-type SNHG15 associated with higher proliferation rate of leukemic blasts when compared with the
cytosine-to-thymidine variant. We conclude that recurrent genetic variants of lncRNA that are expressed
in the leukemic blasts of CN-AML patients have prognostic and potential biological significance.

Introduction
Acute myeloid leukemia (AML) is heterogeneous with
regard to the patients’ clinical course and the underlying
molecular lesions that drive the disease.1-2 Research efforts
of the past four decades have identified a growing list of
genetic alterations associated with clinical outcome that
could be used as biomarkers for the risk stratification of the
patients’ treatment. These alterations include chromosomal
abnormalities,3-5 gene mutations,6-11 and aberrant expression
of RNA transcripts.12-16 The advent of next-generation
sequencing has revealed that AML displays notable heterogeneity at the level of isolated cases; leukemic blasts of individual AML patients represent, in many instances, the sum
of distinct clonal subpopulations, within which mutations
in different genes co-exist and co-operate.17,18 While such
sequencing efforts continue to expand our understanding of
AML pathogenesis, the majority of them are focused on the
protein-coding fraction of the genome, which is, comparatively, its smallest part.19
The non-protein-coding part of the genome, a large fraction of which is actively transcribed into non-coding RNA,
is gaining gradual recognition for its important regulatory
role.20,21 Long non-coding RNA (lncRNA), which are transcripts longer than 200 nucleotides and, per definition, lack
protein-coding potential, regulate many key cellular functions in health and disease.22-24 Deregulated expression of
individual lncRNA has been demonstrated to significantly
affect the cancer phenotype and patients’ clinical outcome.25-29 We and others have previously shown that aberrant expression of small subsets of lncRNA independently
associate with the clinical outcome of patients with cytogenetically normal AML (CN-AML).30-33 With regard to variations in the nucleotide sequences of lncRNA, it has previously been reported that disease-associated single
nucleotide polymorphisms (SNP) are enriched in the genetic
loci encoding these transcripts.34-36 In addition, acquired
mutations of lncRNA that are recurrently detectable in the
leukemic blasts have previously been identified.37 However,
to our knowledge, their prognostic and biologic significance
in AML have not yet been studied.
Herein, we analyzed whole transcriptome sequencing
data of younger adults with the goal to evaluate the clinical
and biological relevance of lncRNA variants in CN-AML.
We used a panel of currently available databases of human
genomic polymorphisms to annotate recurrent genetic variants located within expressed lncRNA. We show that a subset of these variants independently associates with clinical
outcome of CN-AML patients.

Methods
Patients and treatment
Exploratory analysis was conducted in pretreatment bone marrow (BM) or blood samples from 377 younger adults (aged <60
years; range, 18-59 years) with de novo CN-AML. Patients were
treated with intensive, first-line chemotherapy on Cancer and
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Leukemia Group B (CALGB)/Alliance for Clinical Trials in
Oncology (Alliance) trials. Confirmatory analyses were conducted
in a set of 135 CN-AML patients (75 of whom were younger than
60 years and 60 were older) enrolled on clinical trials of the
German AML Cooperative Group (AMLCG).38,39
All patients provided written informed consent regarding the
research use of their specimens. All study protocols were in accordance with the Declaration of Helsinki and approved by
Institutional Review Boards at each center.

Cytogenetic and molecular analyses
Cytogenetic analyses of CALGB/Alliance patients were performed in CALGB/Alliance-approved institutional laboratories
and results were confirmed by central karyotype review.40 The
diagnosis of normal karyotype was based on analysis of ≥20
metaphases obtained from BM specimens subjected to short-term
(24- or 48-hour) unstimulated cultures.40
Mutational analyses of patient samples were conducted with
Sanger sequencing (for the CEBPA gene), fragment analysis (for
detection of FLT3-internal tandem duplications [FLT3-ITD]) and
targeted amplicon sequencing (for all other prognostic gene mutations), as reported previously.31,41-43 Molecular and cytogenetic profiling of the AMLCG cohort were obtained as described previously.38,39

Transcriptome analyses
RNA samples of the patients treated on CALGB/Alliance protocols were analyzed with total RNA sequencing (RNA Seq) after
depletion of ribosomal and mitochondrial RNA using the Illumina
HiSeq 2500 platform. The results of the RNA Seq analysis have
been deposited in the functional genomics data repository GEO
and are publicly available under the accession number
GSE137851. Patients in the AMLCG cohort were analyzed with
RNA Seq following selection for poly-adenylated transcripts
(poly-A RNA Seq) as previously described.16
For exploratory analyses, after quality control, adaptor-trimmed
50 base-pair-long paired-end reads were mapped to the human
reference genome and variant calling was performed following the
Genome Analysis Toolkit best practice recommendations for RNA
Seq datasets.44 A two-pass variant calling approach was applied to
ensure variant detection and depth of coverage (Figure 1). Unique
variant positions were identified on non-coding transcripts that do
not overlap with coding exons and are located in low-complexity
regions of the genome (i.e., excluding repeat masked regions and
segmental duplications). These variants were further evaluated for
associations with clinical outcome and the expression levels of
other RNA transcripts.

Statistical analyses
Clinical endpoint definitions are provided in the Online
Supplementary Appendix. For each examined lncRNA variant, only
patients with detectable expression of the lncRNA and adequate
coverage of the variant position (i.e., depth of coverage >8) were
analyzed. The estimated probabilities of disease-free (DFS), overall (OS) and event-free (EFS) survival were calculated using the
Kaplan–Meier method, and the log-rank test evaluated differences
between survival distributions. Cox proportional hazard models
were used to calculate hazard ratios for DFS, OS and EFS.45
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Multivariable proportional hazards models were constructed
using a backward selection procedure.45 All statistical analyses
using CALGB/Alliance data were performed by the Alliance
Statistics and Data Center.

detection of wild-type genotype in at least 5% of the samples, and iii) detection of variant allele frequency above 0.4
in at least 5% of the samples (Figure 1). Based on these criteria, 981 variants were selected for further analyses (Online
Supplementary Table S1).

In vitro experiments
LncRNA wild-type and variant transcripts were amplified with
Phusion high fidelity polymerase by polymerase chain reaction
(PCR). Amplicons were cloned into pcDNA using the Gibson
technique, according to standard protocols. For primer sequences
and further experimental details please see the Online
Supplementary Appendix. K-562 and THP-1 cells were transfected
with vectors containing either a cytosine (C)-to-thymidine (T)
variant in the lncRNA SNHG15 (SNHG15varT) or wild-type
lncRNA SNHG15 (SNHG15wt); cells were also transfected with
empty pcDNA3.1 and were used as controls. Cell viability and
apoptosis were assessed with annexin V staining. The colorimetric
MTT assay was used to assess the proliferative capacity of the
transfected blasts.

Results
Detection of genetic variants in the non-coding
transcriptome of younger adults with cytogenetically
normal acute myeloid leukemia
In order to examine whether recurrent genetic variants
are present in the non-coding transcriptomes of CN-AML
patients, we first analyzed total RNA sequencing data of
377 younger adults with CN-AML. In order to identify
unequivocally non-coding genetic variants and to avoid
ambiguity in their genomic location, we excluded from further analyses all variants, which overlapped with exons of
protein-coding genes and those that mapped to segmental
duplications or other repeat regions of the genome.
In order to evaluate the clinical and functional relevance
of the lncRNA variants, additional filters were applied.
Specifically, we focused on the variants that displayed: i)
adequate expression and coverage in at least 100 samples
(approximately 25% of a total number of samples), ii)

Detection of long non-coding RNA variants in the
Cancer Genome Atlas (TCGA) dataset
In order to examine the validity and reproducibility of our
experimental pipeline and results, we queried the publicly
available TCGA total RNA Seq dataset.8 It is noteworthy
that the TCGA dataset was generated with a different RNA
Seq technique (i.e., poly-A RNA Seq), which is less suitable
for the interrogation of the non-coding fraction of the transcriptome.46 In addition, a relatively small number of
patients in the TCGA cohort represent CN-AML cases (i.e.,
44 of the 196 available cases).8 Despite these limitations,
277 out of the 981 variants that we tested were detectable
in the transcriptomes of the CN-AML cases included in the
TCGA study (Online Supplementary Table S2).
For a subset of TCGA cases, DNA sequencing data from
both leukemic blasts and germline material are available in
addition to the transcriptome sequencing data. We therefore sought: i) to validate whether the presence of the
detected variants in the transcriptome is also detectable at
the DNA level and ii) to examine whether these variants are
bona fide acquired genetic events or are present in the
germline configuration of the AML patient genomes. As the
sequencing technique that was used to analyze the TCGA
dataset (i.e., exome sequencing) preferentially captures and
interrogates the coding fraction of the genome, only 20 variant positions were available for analyses at the DNA level.
Overall, there was a complete concordance between the
detection of a variant in the transcriptome and its detection
in the genome. Furthermore, 11 of these variants were
detected in both leukemic blasts and non-leukemic tissues
and thus could be considered as germline genetic variants,
whereas nine variants were only detectable in leukemic
samples and could therefore represent acquired mutations
(Online Supplementary Table S2).

Figure 1. Outline of the two-pass experimental approach for the identification of recurrent genetic variants located within long non-coding RNA in younger adult
patients with cytogenetically normal acute myeloid leukemia. In the first pass, variant calling was performed on alignment results (i.e., BAM files) following the
Genome Analysis Toolkit (GATK) best practice recommendations for RNA sequencing datasets. Variants of non-coding transcripts that do not overlap with coding
exons and are not located in low-complexity regions of the genome were selected. In the second pass, Samtools pile-up programs were used to identify sequencing
depth, quality and alternative allele counts on selected unique variant positions. Resulting visual component framework (VCF) files were consolidated with annotation
and the final variant call matrix was generated.
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A
Figure 2. Outcome of younger adult
patients with cytogenetically normal acute
myeloid leukemia who harbored the C-to-T
variant of the RP5-1074L1.4 long non-coding RNA (IncRNA) (RP5-1074L1.4varT) and
of those who had the wild-type lncRNA
(RP5-1074L1.4wt). (A) Disease-free survival, (B) overall survival and (C) event-free
survival.

B

C
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Prognostic significance of recurrent long non-coding
RNA variants in acute myeloid leukemia
We proceeded to examine the associations of the lncRNA
variants with the clinical outcome of younger patients with
CN-AML. Of the variants tested, 41 associated with more
than one outcome endpoint (DFS, OS and/or EFS; Online
Supplementary Table S3) above a threshold level of significance (P<0.05). There was no association between the presence of lncRNA variants and complete remission rates in
our cohort.
Among the variants that showed significant association
with clinical outcome in our dataset were a C-to-T variant
in the lncRNA RP5-1074L1.4 (RP5-1074L1.4varT), and
SNHG15varT, a C-to-T variant in the lncRNA SNHG15.
In patients with detectable RP5-1074L1.4 expression
(n=243), the presence of the RP5-1074L1.4varT was found
in 156 (64%) of them. Patients with the RP5-1074L1.4varT
had longer DFS (P<0.001) than patients with wild-type
RP5-1074L1.4 (RP5-1074L1.4wt); 5 years after diagnosis
44% of the RP5-1074L1.4varT patients were alive and
leukemia-free in contrast to only 26% of those with RP51074L1.4wt. RP5-1074L1.4varT was also associated with
longer EFS (P<0.001; 5-year rates: 38% vs. 21%) and
showed a trend for longer OS (P=0.09; 5-year rates: 43% vs.
34%; Figures 2 A to C; Online Supplementary Table S4).
Among patients who expressed the SNHG15 lncRNA
(n=306), SNHG15varT was detected in 78% of them
(n=239). Patients who expressed the SNHG15varT had
longer DFS (P=0.04; 5-year rates: 37% vs. 22%) than
patients who expressed the SNHG15wt. SNHG15varT
expressers also had longer EFS (P=0.04; 5-year rates: 31%
vs. 19%) and a trend for longer OS (P=0.07; 5-year rates:
41% vs. 32%) compared with SNHG15wt expressers
(Figures 3A to C; Online Supplementary Table S5).
Finally, we examined whether genetic variants were
detectable in the set of 24 lncRNA, whose expression levels
were previously shown to associate with the clinical outcome of younger adults with CN-AML.30 We found seven
such variants in three of the prognostic lncRNA (annotated
in bold lettering in the Online Supplementary Table S1). A
guanosine (G)-to-C variant in the lncRNA AL122127.25
(AL122127.25varC) was the only one that associated with
patient outcome. AL122127.25varC was detected in 72 of
the 257 patients who expressed the AL122127.25 lncRNA
(i.e., 28% of the AL122127.25 expressers). The presence of
AL122127.25varC significantly associated with shorter DFS
(P=0.01; 5-year rates: 17% vs. 35%), OS (P=0.01; 5-year
rates: 22% vs. 40%) and EFS (P=0.002; 5-year rates: 12% vs.
30%; Online Supplementary Figures S1A to C; Online
Supplementary Table S6) in younger adult CN-AML patients.
Notably, the presence of AL122127.25varC had no impact
on the expression levels of the AL122127.25 transcript,
when compared to the AL122127.25wt (Online
Supplementary Figure S2).

Associations of long non-coding RNA variants with
pretreatment clinical and molecular characteristics
Next, we examined potential associations of RP51074L1.4varT, SNHG15varT and AL122127.25varC with
pretreatment clinical characteristics and prognostic molecular features of younger adult CN-AML patients. Overall,
there were only minor differences in these features
between variant and wild-type lncRNA expressers. Patients
expressing the RP5-1074L1.4varT were more likely to harbor tyrosine kinase domain mutations of the FLT3 gene
1038

Table 1. Multivariable analyses of outcome in younger adult patients
with cytogenetically normal acute myeloid leukemia by expression of
the C-to-T variant of the RP5-1074L1.4 long non-coding RNA (IncRNA)
(RP5-1074L1.4varT) versus the wild-type lncRNA (RP5-1074L1.4wt).

DFS
Variables in final models

HR
(95% CI)

RP5-1074L1.4,
0.54
varT vs. wild-type
(0.37-0.77)
FLT3-ITD,
2.29
present vs. absent
(1.59-3.30)
WT1,
1.85
mutated vs. wild-type
(1.04-3.27)
MN1 expression,
1.55
high vs. low
(1.07-2.24)
CEBPA,
double-mutated vs. wild-type
NPM1,
mutated vs. wild-type

P
<0.001
<0.001
0.04
0.02
-

EFS
HR
P
(95% CI)
0.54
<0.001
(0.40-0.75)
2.16
<0.001
(1.54-3.02)
1.90
0.006
(1.20-3.02)
0.36
0.001
(0.21-0.61)
0.41
<0.001
(0.28-0.58)

DFS: disease-free survival; EFS: event-free survival; FLT3-ITD: internal tandem duplication of the FLT3 gene; HR: hazard ratio; CI: confidence intervals; varT: C-to-T variant; vs.:
versus. NOTE: Hazard ratios greater than (less than) 1.0 indicate higher (lower) risk
for relapse or death (disease-free survival) or death (overall survival) or for failure to
achieve complete remission, relapse or death (event-free survival) for the first category listed for the categorical variables. Variables considered for model inclusion were:
RP5-1074L1.4 (varT vs. wild-type), age (as a continuous variable, in 10-year increments), sex (male vs. female), race (white vs. non-white), white blood cell count (as
a continuous variable, in 50-unit increments), hemoglobin (as a continuous variable,
in 1-unit increments), platelet count (as a continuous variable, in 50-unit increments),
extramedullary involvement (present vs. absent), ASXL1 mutations (mutated vs.
wild-type), CEBPA mutations (double-mutated vs. single-mutated or wild-type),
DNMT3A mutations (mutated vs. wild-type), FLT3-ITD (present vs. absent), FLT3-TKD
(present vs. absent), IDH1 mutations (mutated vs. wild-type), IDH2 mutations (mutated vs. wild-type), NPM1 mutations (mutated vs. wild-type), RUNX1 mutations (mutated vs. wild-type), TET2 mutations (mutated vs. wild-type), WT1 mutations (mutated
vs. wild-type), ERG expression levels (high vs. low), BAALC expression levels (high vs.
low), MN1 expression levels (high vs. low), miR-181a expression levels (high vs. low),
miR-3151 expression (expressed vs. not expressed), and miR-155 expression levels
(high vs. low).

(FLT3-TKD) than patients who expressed the RP51074L1.4wt (P=0.03; 12% vs. 4%; Online Supplementary
Table S7). Patients expressing the SNHG15varT were older
(P=0.03), more likely to be Caucasian (P=0.02) and more
likely to have low expression of the MN1 gene (P=0.05;
Online Supplementary Table S8) than SNHG15wt expressers.
With regard to the lncRNA AL122127.25, there were no significant differences in the clinical features or frequencies of
prognostic gene mutations or gene expression between
AL122127.25varC and AL122127.25wt expressers (Online
Supplementary Table S9).

Multivariable analyses
In order to examine prognostic significance of the detected lncRNA variants in the context of other established clinical and molecular prognostic markers, we constructed multivariable models.
Expression of RP5-1074L1.4varT was a significant marker
for longer DFS (hazard ratio [HR]: 0.54; P<0.001) and longer
EFS (HR: 0.54; P<0.001) after adjusting for other covariates
(Table 1). Expression of SNHG15varT significantly associated with longer DFS (HR: 0.63; P=0.02), longer OS (HR: 0.63;
P=0.008) and longer EFS (HR: 0.68; P=0.02) after adjusting
for other variables for each outcome endpoint (Table 2).
Finally, expression of the AL122127.25varC was an independent marker of shorter OS (HR: 1.57; P=0.009) and
shorter EFS (HR: 1.59; P=0.004) after adjusting for other
covariates (Online Supplementary Table S10).
haematologica | 2022; 107(5)
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Table 2. Multivariable analyses of outcome in younger adult patients with cytogenetically normal acute myeloid leukemia by expression of the Cto-T variant of the SNHG15 long non-coding RNA (lncRNA) (SNHG15varT) versus the wild-type lncRNA (SNHG15wt).

Variables in final models
SNHG15,
varT vs. wild-type
FLT3-ITD,
present vs. absent
WT1,
mutated vs. wild-type
MN1 expression,
high vs. low
DNMT3A,
mutated vs. wild-type
miR-155 expression,
high vs. low
Extramedullary disease,
Present vs. absent
Hemoglobin,
continuous, 1-unit increments
Age,
continuous, 10-year increments
NPM1,
mutated vs. wild-type
CEBPA,
double-mutated vs. wild-type

DFS

OS

EFS

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

0.63
(0.34-0.81)
1.68
(1.08-2.60)
1.91
(1.01-3.55)
1.51
(1.04-2.20)
2.11
(1.43-3.12)
1.85
(1.18-2.91)
0.61
(0.39-0.95)
0.87
(0.79-0.96)
-

0.02

0.008

0.02
<0.001

0.004

0.68
(0.22-0.57)
2.08
(1.57-2.76)
-

0.03

0.63
(0.45-0.89)
2.48
(1.83-3.35)
1.78
(1.21-2.63)
-

-

-

-

<0.001

-

-

-

-

0.007

-

-

-

-

0.03

-

-

-

-

0.004

0.004

0.89
(0.83-0.95)
-

0.001

-

-

0.45
(0.34-0.62)
0.35
(0.22-0.57)

<0.001

-

0.89
(0.83-0.96)
1.29
(1.12-1.48)
0.51
(0.37-0.71)
0.49
(0.30-0.80)

0.02
0.04

-

<0.001

<0.001
0.005

-

-

<0.01

DFS: disease-free survival; OS: overall survival; EFS: event-free survival; FLT3-ITD: internal tandem duplications of the FLT3 gene; HR: hazard ratio; CI: confidence intervals; varT: Cto-T variant; vs.: versus. NOTE: Hazard ratios greater than (less than) 1.0 indicate higher (lower) risk for relapse or death (disease-free survival) or death (overall survival) or for
failure to achieve complete remission, relapse or death (event-free survival) for the first category listed for the categorical variables. Variables considered for model inclusion
were SNHG15 (varT vs. wild-type), age (as a continuous variable, in 10-year increments), sex (male vs. female), race (white vs. non-white), white blood cell count [(WBC) as a
continuous variable, in 50-unit increments], hemoglobin (as a continuous variable, in 1-unit increments), platelet count (as a continuous variable, in 50-unit increments),
extramedullary involvement (present vs. absent), ASXL1 mutations (mutated vs. wild-type), CEBPA mutations (double-mutated vs. single-mutated or wild-type), DNMT3A mutations (mutated vs. wild-type), FLT3-ITD (present vs. absent), FLT3-TKD (present vs. absent), IDH1 mutations (mutated vs. wild-type), IDH2 mutations (mutated vs. wild-type),
NPM1 mutations (mutated vs. wild-type), RUNX1 mutations (mutated vs. wild-type), TET2 mutations (mutated vs. wild-type), WT1 mutations (mutated vs. wild-type), ERG expression levels (high vs. low), BAALC expression levels (high vs. low), MN1 expression levels (high vs. low), miR-181a expression levels (high vs. low), miR-3151 expression
(expressed vs. not expressed), and miR-155 expression levels (high vs. low).

RP5-1074L1.4 is an intronic lncRNA, which is embedded
in intron 7 of the protein-coding SLC16A4 transcript. In
order to ensure that the prognostic effect of RP51074L1.4varT was not due to perturbation of the expression levels of SLC16A4, we compared the SLC16A4 transcript abundance between 87 patients who expressed the
RP5-1074L1.4wt and 156 patients who expressed the RP51074L1.4varT. We found no significant difference in expression levels of SLC16A4 between these two patient groups
(Online Supplementary Figure S3).

Evaluation of the prognostic significance of long
non-coding RNA variants in an independent cohort
of cytogenetically normal acute myeloid leukemia
patients
In order to examine whether our findings were reproducible in an independent cohort of CN-AML patients, we
examined patients treated on AMLCG protocols,38,39 who had
available clinical outcome data, and were analyzed with
poly-A selected RNA Seq (n=135). As was the case with the
TCGA dataset,8 the use of an alternative RNA Seq technique
limited the number of lncRNA variants that could be detected and analyzed. The lncRNA transcripts, whose variants
showed the strongest association with prognosis in our initial
cohort were not captured by the poly-A RNA Seq and could
not, therefore, be analyzed for associations with clinical outcome. Despite this limitation, there was concordance in the
findings between the two cohorts. SNHG15varT was the
haematologica | 2022; 107(5)

one detectable lncRNA variant, which associated with multiple outcome endpoints in the AMLCG dataset. Specifically,
the SNHG15varT was detected in 103 of the 120 AMLCG
CN-AML patients who expressed the SNHG15 lncRNA. In
agreement with our findings in the CALGB/Alliance dataset,
the presence of SNHG15varT associated with longer DFS
(P=0.04; Figure 3D) and EFS (P=0.007, Figure 3E), but not OS
(P=0.17), in the AMLCG cohort.

Expression levels of SNHG15 in normal hematopoiesis
In order to further examine the functional significance of
the lncRNA, which harbor prognostic variants we sought to
determine their expression patterns during normal
hematopoiesis. To this end, we used publicly available
datasets of normal hematopoietic cells analyzed with
microarrays or RNA Seq and deposited in the BloodSpot
portal (www.bloodspot.eu). Of the lncRNA with prognostic genetic variants, only SNHG15 was annotated in the
database and could be further analyzed. We found that
SNHG15 was most abundantly expressed in common
myeloid progenitors, granulocyte monocyte progenitors
and megakaryocyte-erythroid progenitors. It was also highly expressed in hematopoietic stem cells and lymphoid cell
populations. Among mature cell populations, SNHG15 was
overexpressed in monocytes, whereas its expression levels
were the lowest in polymorphonuclear leucocytes of the
bone marrow and peripheral blood (Online Supplementary
Figure S4).
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D

Figure 3. Prognostic significance of long non-coding
RNA variants across different cytogenetically normal acute myeloid leukemia cohorts. (A) Diseasefree survival, (B) overall survival and (C) event-free
survival of younger adult cytogeneti-cally normal
acute myeloid leukemia (CN-AML) patients in the
CALGB/Alliance cohort who had the C-to-T variant of
the SNHG15 long non-coding RNA (SNHG15varT)
and of patients with the wild-type SNHG15 lncRNA
(SNHG15wt). (D) Disease-free survival and (E) eventfree survival of CN-AML patients in the AMLCG cohort
with the C-to-T variant of the SNHG15 lncRNA
(SNHG15varT) and of those the wild-type SNHG15
lncRNA (SNHG15wt).

E

Functional relevance of prognostic long non-coding
RNA variants
We hypothesized that in addition to associations with
outcome, the presence of genetic variants in lncRNA could
have a functional impact and affect AML blast viability and
proliferation. We focused on the lncRNA SNHG15varT,
whose prognostic significance was validated in an independent cohort of AML patients. We isolated total RNA
from AML cell lines and amplified both the SNHG15wt
and SNHG15varT transcripts. We cloned the amplicons
into pcDNA3.1 expression vectors and transfected two
AML cell lines (i.e., K-562 and THP-1 cells). Expression levels of the SNHG15 lncRNA were similar in cells transfected
with the SNHG15wt and those transfected with
SNHG15varT-containing vectors, when compared with the
empty vector controls (Figures 4A and B). Regarding cell
haematologica | 2022; 107(5)

viability, ectopic overexpression of the SNHG15wt and the
SNHG15varT led to a discreet but consistent decrease in
cell viability across cell lines, which did not reach statistical
significance (Figures 4C and D).
In order to further evaluate the effect of SNHG15 on the
growth kinetics of the AML cells, we performed colorimetric MTT assays. Forced overexpression of the SNHG15varT
had no significant effect on blast growth when compared
with controls. In contrast, overexpression of the
SNHG15wt led to increased proliferative capacity of the
leukemic cells when compared with both controls and cells
overexpressing the SNHG15varT (Figures 4E and F). These
findings are in line with our prognostic observations and
the inferior outcome of CN-AML patients who express
SNHG15wt, compared with those who express
SNHG15varT.
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Discussion
lncRNA are gaining recognition as important molecular
mediators and regulators of key cellular functions in health
and disease.22-29 In AML, lncRNA have been shown to associate with the clinical outcome of both younger and older
patients.30-33 However, these previous studies have focused
on the expression levels of the lncRNA transcripts; the
effect of genetic variants within lncRNA has not been
extensively studied. Accumulating evidence suggests that
such genetic variants could impact on the function of the
lncRNA and be relevant for disease pathogenesis.47 In support of this view, disease-associated SNP are more frequently found in regions of the genome that encode for non-coding RNA transcripts in several types of solid tumors34,35 and
in AML.34,36 These findings suggest that the presence of a
variant in the non-coding transcriptome could be the functional link that explains how genetic variants that do not
alter the structure of protein molecules associate with
malignant phenotypes. Recently, Klco et al.37 have reported
the acquisition of somatic mutations in lncRNA transcripts
of AML patients, as demonstrated by analyses of the
leukemic blasts in parallel with germline material.
However, the prognostic value of these mutations could not
be tested due to sample size limitations. Herein, we analyzed total RNA Seq data of younger adult patients with
CN-AML with the goal to detect recurrent lncRNA variants
and evaluate their prognostic and biologic significance.
We used a stringent approach for detecting and filtering
sequence variations of lncRNA. We generated a list of 981
recurrent variants, which are located within lncRNA in
younger adult patients constituting the CALGB/Alliance
cohort, and which had adequate sample sizes for meaningful survival analyses. In order to study potential associations
of the detected variants with clinical outcome, we individualized analysis for each variant and limited comparisons to
the group of patients that were expressers of the corresponding lncRNA transcript (i.e., we compared the expressers of
a variant to the expressers of the wild-type lncRNA). Of the
981 candidate variants, a subset of 41 significantly associated with at least two clinical outcome endpoints of younger
adults with CN-AML. LncRNA genetic variants RP51074L1.4varT and SNHG15varT were significantly associated with prognosis. RP5-1074L1.4 has not been previously
associated with cancer pathogenesis or clinical outcome of
cancer patients. In contrast, SNHG15, a MYC-regulated
lncRNA, which harbors a small nucleolar RNA in one of its
introns, has been implicated in the pathogenesis of multiple
solid malignancies. SNHG15 has been shown to interact
with the protein AIF and to associate with a clinically
aggressive and prognostically unfavorable subset of colorectal carcinomas.48 SNHG15 has also been associated with
aggressive phenotypes of hepatocellular and breast carcinomas via sponging and inhibiting the function of microRNAs
141-3p and 211-3p.49,50
Patients who expressed the RP5-1074L1.4varT had more
favorable outcome (i.e., longer DFS, EFS and a trend for
longer OS) than RP5-1074L1.4wt expressers. SNHG15varT
also associated with better prognosis and SNHG15varT
expressers had longer DFS and EFS compared with patients
who expressed the SNHG15wt lncRNA.
Further, we examined whether recurrent genetic variants
could be detected in lncRNA previously reported to be
prognostic in younger adults with CN-AML.30 A G-to-C
variant in the prognostic lncRNA AL122127.25
1042

(AL122127.25varC) significantly associated with clinical
outcome of CN-AML patients. Specifically, expression of
the AL122127.25varC associated with shorter DFS, OS and
EFS. Notably, the expression levels of the AL122127.25
lncRNA were not significantly affected by the presence of
the AL122127.25varC. Thus, both the abundance and the
nucleotide sequence of the AL122127.25 lncRNA associate
with the clinical outcome of CN-AML patients via potentially independent mechanisms.
Currently, there is limited availability of AML datasets
analyzed with RNA Seq techniques (i.e., with total RNA
Seq) that are suitable for in-depth analyses of the non-coding transcriptome. In order to examine whether our observations could be reproduced in other datasets, we examined the presence of our curated variant list in an independent cohort of CN-AML patients who were treated on
AMLCG protocols. As expected, the use of a different RNA
Seq technique significantly limited the number of lncRNA
transcripts that we could interrogate. Nevertheless,
SNHG15varT was detectable and associated with longer
DFS and EFS of the AMLCG patients, similarly to its prognostic effect in the CALGB/Alliance dataset.
Given the constantly increasing number of prognostic
molecular alterations in AML, it is important to examine
the prognostic value of novel markers in the context of
other established clinical and molecular prognosticators. It
is thus noteworthy that the lncRNA variants that we examined
(RP5-1074L1.4varT,
SNHG15varT,
and
AL122127.25varC) did not show associations with gene
mutations that are currently used for the risk stratification
of the treatment of AML patients.11 Mutations in the
CEBPA, RUNX1, ASXL1 and NPM1 genes as well as the
presence of the FLT3-ITD were similarly distributed
between expressers of the lncRNA variants and expressers
of the wild-type transcripts. In addition, in formal multivariable analyses that included prognostic clinical and
molecular parameters, RP5-1074L1.4varT, SNHG15varT,
and AL122127.25varC retained their prognostic significance
after adjusting for other covariates. Consequently, detection
of these variants could provide additional prognostic information and further refine risk-stratification of CN-AML
patients.
In addition to testing their prognostic significance, we
sought to evaluate whether the presence of recurrent variants in lncRNA sequences has functional implications.
We focused on SNHG15 lncRNA and performed overexpression
experiments
with
SNHG15wtand
SNHG15varT-containing vectors in the K-562 and THP-1
cell lines. Overexpression of the SNHG15varT had no significant effect on cell viability and no evident impact on
cell proliferation, compared with controls. In contrast,
overexpression of the SNHG15wt led to a significant
increase in the proliferative capacity of the leukemic
blasts in both cell lines that were tested. Despite the limitations of in vitro assays, these results indicate that
expression of SNHG15wt associates with a more aggressive disease phenotype, when compared with
SNHG15varT, and are in line with the inferior clinical
outcome of SNHG15wt-expressers.
In summary, we have performed comprehensive characterization of genetic variants within lncRNA in younger
adults with CN-AML. We present analyses that support the
prognostic and potential biologic significance of lncRNA
variants in CN-AML. We believe that our work will serve
as a useful starting point for further studies on the role of
haematologica | 2022; 107(5)
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Figure 4. Biologic significance of recurrent long non-coding RNA variants in younger adult cytogenetically normal acute myeloid leukemia patients. Fold changes
of SNHG15 long non-coding RNA (lncRNA) expression levels (A and B), percent of viable cells (C and D) and proliferation (E and F) of acute myeloid leukemia cell
lines transfected with empty pcDNA3, SNHG15wt-containing or SNHG15varT-containing vectors. Results for K-562 (A, C and E) and THP-1 (B, D and F) cells are
depicted. Proliferation is assessed with the MTT colorimetric assay, by light absorbance. *P<0.05; **P<0.01; ***P<0.001; N.S: not significant.

genetic variants in the non-coding transcriptome of cancer
patients.
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